N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin–fibrate combination

Zeman, Miroslav; Žák, Aleš; Vecka, Marek; Tvrzická, E; Písaříková, A.; Staňková, Barbora

doi:10.1016/j.jnutbio.2005.08.007

Cited by 51 publications

(39 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 Three months of supplementation with n-3 PUFA (3.6 g daily, 57.4% eicosapentaenoic acid and 28.7% docosahexaenoic acid) marginally reduced absolute albumin excretion but not UACR in 24 patients with type 2 diabetes mellitus. 31 Our study suggests that, at the dosage used and for the observation time considered, the two treatments had no obvious harmful or beneficial effects on albumin excretion. This is in line with their good safety profile on renal function in the GISSI-HF trial 18,19 or in clinical practice.…”

Section: Masson Et Al Prognostic Value Of Albumin Excretion In Hfmentioning

confidence: 61%

Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure

Masson¹,

Latini²,

Milani³

et al. 2010

Circ: Heart Failure

110

View full text Add to dashboard Cite

on behalf of the GISSI-HF InvestigatorsBackground-Increased urinary excretion of albumin is an early sign of kidney damage and a risk factor for progressive cardiovascular and renal diseases and heart failure. There is, however, only limited information on the prevalence and prognostic role of urinary albumin excretion in patients with established chronic heart failure. Methods and Results-A total of 2131 patients enrolled in 76 sites participating in the GISSI-Heart Failure trial provided a first morning spot sample of urine at any of the clinical visits scheduled in the trial to calculate the urinary albumin-to-creatinine ratio. The relation between log-transformed urinary albumin-to-creatinine ratio and all-cause mortality (428 deaths, time from urine collection to event or censoring) was evaluated with Cox multivariable models adjusted for all significant risk factors at the time of urine collection, in the study population, and in patients without diabetes or hypertension. Almost 75% of the patients had normal urinary albumin excretion, but 19.9% had microalbuminuria (30 to 299 mg/g creatinine) and 5.4% had overt albuminuria (Ն300 mg/g). There was a progressive, significant increase in the adjusted rate of mortality in the study population (hazard ratio, 1.12; 95% CI, 1.05 to 1.18 per 1-U increase of log(urinary albumin-to-creatinine ratio), Pϭ0.0002) and in the subgroup of patients without diabetes or hypertension. Randomized treatments (n-3 polyunsaturated fatty acids or rosuvastatin) had no major impact on albumin excretion. Conclusions-Independently of diabetes, hypertension, or renal function, elevated albumin excretion is a powerful prognostic marker in patients with chronic heart failure. (Circ Heart Fail. 2010;3:65-72.)

show abstract

Section: Masson Et Al Prognostic Value Of Albumin Excretion In Hfmentioning

confidence: 61%

Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure

Masson¹,

Latini²,

Milani³

et al. 2010

Circ: Heart Failure

110

View full text Add to dashboard Cite

show abstract

“…In another short-term study of 26 patients with type 2 diabetes [40], 4.8 g/day of O3FAs reduced the concentration of large VLDL and small HDL particles, without significant changes in LDL particle size or number. Finally, add-on O3FAs (3.6 g/day) administered to patients with type 2 diabetes, who had not reached lipid targets despite treatment with pravastatin plus fenofibrate, significantly lowered plasma homocysteine levels in addition to its lowering of triglyceride levels [41].…”

Section: Type 2 Diabetesmentioning

confidence: 98%

Fish oil in the treatment of dyslipidemia

Goldberg

Sabharwal

2008

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…The effect of fibrates and n-3 PUFA is additive in lowering TAG concentrations 214 . In patients with diabetic dyslipidemia treated with statin-fibrate combination, supplementation with n-3 PUFA further decreased plasma TAG, total homocysteine and microalbuminuria 215 . A randomised double-blind trial in CHD patients receiving either statins or fibrates showed that lipid lowering drugs affect EFA metabolism.…”

mentioning

confidence: 88%

Fatty Acids as Biocompounds: Their Role in Human Metabolism, Health and Disease - A Review. Part 2: Fatty Acid Physiological Roles and Applications in Human Health and Disease

Kremmyda¹,

Tvrzická²,

Staňková³

et al. 2011

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

154

134

View full text Add to dashboard Cite

Background. This is the second of two review parts aiming at describing the major physiological roles of fatty acids, as well as their applications in specific conditions related to human health.Results. The review included the current literature published in Pubmed up to March 2011. In humans, fatty acids are a principle energy substrate and structural components of cell membranes (phospholipids) and second messengers. Fatty acids are also ligands of nuclear receptors affecting gene expression. Longer-chain (LC) polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and arachidonic acid are precursors of lipid mediators such as eicosanoids (prostaglandins, leukotrienes, thromboxanes), resolvins and neuroprotectins. Lipid mediators produced by EPA and DHA (LC n-3 PUFA; mainly found in oily fish) are considered as inflammation-resolving, and thus, fish oil has been characterised as antiinflammatory. Recommendations for EPA plus DHA intake from oily fish vary between 250-450 mg/day. Dietary reference values for fat vary between nutrition bodies, but mainly agree on a low total and saturated fat intake. The existing literature supports the protective effects of LC n-3 PUFA (as opposed to n-6 PUFA and saturated fat) in maternal and offspring health, cardiovascular health, insulin sensitivity, the metabolic syndrome, cancer, critically ill patients, and immune system disorders.Conclusion. Fatty acids are involved in multiple pathways and play a major role in health. Further investigation and a nutrigenomics approach to the effects of these biocompounds on health and disease development are imperative and highlight the importance of environmental modifications on disease outcome.humans. Thus, these FA may be characterised as conditionally essential depending on EFA availability. Genetic variation in human desaturase genes affects FA metabolism, plasma lipid profiles, and risk of disease development [5][6][7] . Recommendations for minimum dietary intake of EPA plus DHA vary between 250-450 mg/day 8 , especially for pregnant women and those of reproductive age. Rich sources of LC n-3 PUFA are fish oils and the flesh of oily fish, whereas non-oily (white) fish contain them but in lower amounts.Long-chain PUFA with 18-20 carbon atoms, including EPA and AA, are precursors of eicosanoids (prostaglandins, leucotrienes and thromboxanes), which have a broad scale of regulatory, autocrine and paracrine effects. Long-chain PUFA with 20 and 22 carbon atoms are precursors of autacoids -resolvins (resolution phase interaction products), lipoxins and neuroprotectins 9 . FA are also ligands of nuclear receptors which take part in the subcellular control of metabolic pathways. Covalent modification of proteins by FA acylation enables their incorporation into membranes. Hydroxy FA are activators of some nuclear factors and are responsible for the expression of proinflammatory cytokines (interleukin (IL)-1,

show abstract

N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin–fibrate combination

Cited by 51 publications

References 45 publications

Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure

Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure

Fish oil in the treatment of dyslipidemia

Fatty Acids as Biocompounds: Their Role in Human Metabolism, Health and Disease - A Review. Part 2: Fatty Acid Physiological Roles and Applications in Human Health and Disease

Contact Info

Product

Resources

About